Back to results
US 2022/0064255 A1Published application
Anti-tcr antibody molecules and uses thereof
AssigneeMarengo Therapeutics, Inc.
InventorsAndreas Loew, Stephen Arkinstall
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of expanding T cells ex vivo comprising contacting the T cells with antibody molecules that bind to TCR Vβ regions. In some embodiments, the T cells comprise one or more nucleic acid molecule encoding an exogenous cellular receptor, for example, a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR).
Claims29
1-179. (canceled)
A method of expanding T cells that expresses a T cell receptor beta variable region (TCRβV) in a T cell population ex vivo, the method comprising:
- contacting the T cell population with a first agent comprising a first domain that binds to a first target molecule that is T cell receptor beta variable beta chain (TCRβV),
- wherein the first agent comprises a second domain that binds to a second target molecule that is a protein expressed on the surface of T cells of the T cell population,
- wherein the first target molecule and the second target molecule are different target molecules,
- wherein the first domain contacts the TCRβV of a T cell receptor (TCR) expressed by the T cells in the T cell population, thereby expanding the T cells in the T cell population, and
- wherein the T cell population is an ex vivo T cell population.
2 more elements
The method of claim 18283, wherein the first domain binds to a TCRβV region of a TCRβV20-1.
Dependencies are inferred from the claim text.